LONDON, UK, 20 December 2007 - SkyePharma PLC (LSE: SKP) today announces it has
revised the agreement with Abbott for the development and commercialization in
the United States of FlutiformTM, the Company's product under development for
the treatment of asthma. Under the terms of the amended agreement, Abbott
assumes the responsibility and costs for additional clinical work required and
agreed upon by the U.S. Food and Drug Administration (FDA) and submitting the
New Drug Application (NDA) for Flutiform.
